



09-19-01

03CO

#3

EXPRESS MAIL CERTIFICATE

Date 9/17/01 Label No. EV 000504944-US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

S. Davis

Name (Print)

D. Davis

Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No: 0632/1G857-US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jon B. KORSHUS et al.

Serial No.: 09/930,657

Group Art Unit: Unassigned

Confirmation No.: 3992

Filed: August 14, 2001

Examiner: Unassigned

For: BORRELIA BURGENDORFERI BACTERIN

RESPONSE

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

September 17, 2001

Sir:

This is in response to the NOTICE TO FILE CORRECTED APPLICATION PAPERS of September 6, 2001. No fee is believed due, however the Commissioner is authorized to charge any fees due to Deposit Account No. 04-0100. Please amend the application as follows:

After the last page, please add the following Abstract which is also provided on a separate sheet attached hereto:


ABSTRACT

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated *Borrelia burgdorferi*, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated *Borrelia burgdorferi* isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first *Borrelia burgdorferi* isolate and a second, non-crossprotective *Borrelia burgdorferi* isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third *Borrelia burgdorferi*. Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated *Borrelia burgdorferi* and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated *Borrelia burgdorferi* and antigenic subunits and a suitable carrier.--

REMARKS

An Abstract of the technical disclosure as required under 37 CFR 1.72 (b) has been provided. Applicants submit that the application is complete.

Respectfully submitted,



Raina Semionow

Reg. No. 39,022

Attorney for Applicants

DARBY & DARBY, P.C.
805 Third Avenue
New York, N.Y. 10022
Phone (212) 527-7700

M:\0632\1G857\RXS0938 WPD

Serial No. 09/930,657
Response to Notice dated September 6, 2001

Docket No. 0632/1G857US2
Page 2



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/930,657	08/14/2001	Jon B. Korshus	0632/1G857-US2

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022



CONFIRMATION NO. 3992

FORMALITIES LETTER



OC000000006517642

Date Mailed 09/06/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE